Oppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Cue Biopharma (CUE – Research Report), with a price target of $10.00. The company’s shares closed yesterday at $1.92.

Gershell covers the Healthcare sector, focusing on stocks such as Catalyst Pharma, Cue Biopharma, and Crinetics Pharmaceuticals. According to TipRanks, Gershell has an average return of 1.6% and a 35.14% success rate on recommended stocks.

Currently, the analyst consensus on Cue Biopharma is a Strong Buy with an average price target of $9.40.

Based on Cue Biopharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.1 million and a GAAP net loss of $11.01 million. In comparison, last year the company earned a revenue of $68 thousand and had a GAAP net loss of $10.96 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cue Biopharma (CUE) Company Description:

Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.